BIOLINERX LTD/S (NASDAQ:BLRX) will be releasing its earnings data before the market opens on Thursday, March 28th.
NASDAQ:BLRX opened at $0.44 on Tuesday. The company has a market capitalization of $46.00 million, a PE ratio of -1.63 and a beta of 1.70. BIOLINERX LTD/S has a 1-year low of $0.38 and a 1-year high of $1.84.
A number of research firms have recently weighed in on BLRX. Oppenheimer set a $3.00 price objective on shares of BIOLINERX LTD/S and gave the company a “buy” rating in a research report on Wednesday, December 12th. HC Wainwright set a $4.00 price target on shares of BIOLINERX LTD/S and gave the stock a “buy” rating in a research report on Tuesday, December 11th. Finally, Maxim Group set a $2.00 price target on shares of BIOLINERX LTD/S and gave the stock a “buy” rating in a research report on Wednesday, December 12th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $2.50.
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.